Cara Therapeutics (CARA) Misses Q4 EPS by 33c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.81), $0.33 worse than the analyst estimate of ($0.48). "The Company did not recognize any revenues during the fourth quarter of 2016 or 2015."

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion